GDPR has contributed to a decline in the number of healthcare professionals disclosing payments or benefits from the pharma industry, says the Association of the British Pharmaceutical Industry.
News
US priority review for Keytruda/chemo combo in first-line squamous NSCLC
US regulators have assigned a priority review to MSD’s application to market the immunotherapy Keytruda in combination with chemotherapy as a first-line treatment for squamous non-small cell lung cancer (NSCLC).
EU green light for Cimzia to treat psoriasis
The European Medicines Agency has approved a label extension for UCB’s Cimzia allowing its use to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
NICE says Tookad too expensive for prostate cancer
The National Institute for Health and Care Excellence has concluded that Steba Biotech’s Tookad is not cost-effective enough to be approved enough for NHS funding to treat prostate cancer.
Gov’t announces £215m investment in NHS health research
The government has announced an investment of £215 million to fund NHS health research aiming to “transform the lives” of millions of people living with a range of conditions.
NICE ‘no’ for Roche’s Ocrevus in primary progressive MS
The National Institute for Health and Care Excellence has concluded that Roche’s Ocrevus should not be funded on the NHS for the treatment of primary progressive multiple sclerosis (PPMS) in adults.
Roche gearing up to file Tecentriq for breast cancer
Roche has unveiled data showing that a combination of Tecentriq and Abraxane significantly slashed the risk of disease worsening or death in some breast cancer patients.
CAR-T therapies leap towards EU approval
The stage has been set for approval of the first chimeric antigen T-cell therapies (CAR-T) in Europe, after Novartis’ Kymriah and Gilead’s Yescarta both won backing from the Committee for Medicinal Products for Human Use (CHMP).
NHS ‘Vanguards’ failing to reach potential, finds NAO
NHS England’s flagship vanguard programme has not delivered the depth and scale of transformed services originally aimed for, according to an investigation by the National Audit Office (NAO).
Celgene, Acceleron to file MDS therapy in the EU, US
Celgene and Acceleron Pharma are preparing to file their experimental myelodysplastic syndromes (MDS) therapy on both sides of the Atlantic on the back of promising data from a late-stage study.
Novartis to spin off eye unit Alcon
Novartis has announced plans to spin off its eye-care unit Alcon into a standalone entity.
Novo’s oral semaglutide bests MSD’s Januvia on HbA1c reduction
Novo Nordisk has presented data from a Phase IIIa study showing that an oral formulation of its GLP-1 analogue semaglutide was better at reducing blood sugar than MSD’s DPP-4 inhibitor Januvia in patients with type II diabetes.
EU approves Pfizer’s Xeljanz for psoriatic arthritis
The European Commission has approved Pfizer’s Xeljanz as a treatment for psoriatic arthritis (PsA), significantly expanding the drug’s scope.
FDA approves Pierre Fabre/Array Biotech melanoma combo
US regulators have issued a green light for Pierre Fabre and Array Biotech’s encorafenib/binimetinib combination therapy for advanced BRAF-mutant melanoma.
NHS England expands health and care record scheme
NHS England has announced two more regions chosen to become Local Health and Care Record Exemplars (LHCRE), tasked with establishing an integrated health and care record across a large population.
